Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Keith J. Chappell, Francesca L. Mordant, Zheyi Li, Danushka K. Wijesundara, Paula Ellenberg, Julia Lackenby, Stacey T. M. Cheung, Naphak Modhiran, Michael S. Avumegah, Christina L Henderson, Kym Hoger, Paul Griffin, Jillian Bennet, Luca Hensen, Wuji Zhang, Thi H. O. Nguyen, Sara Marrero‐Hernández, Kevin J. Selva, Amy W. Chung, Mai H. Tran, Peter Tapley, James Barnes, Patrick C. Reading, Suellen Nicholson, Stavroula Corby, Thomas Holgate, Bruce D. Wines, P. Mark Hogarth, Katherine Kedzierska, Damian F. J. Purcell, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro